Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.68 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2830015 | 0.95 | HDAC1 (0.74) | F10HDAC3HDAC8HDAC1HDAC4 | |
| SCHEMBL8077840 | 0.89 | HDAC1 (0.80) | HDAC3HDAC8HDAC1HDAC4HDAC7 | |
| SCHEMBL2321697 | 0.83 | F10 (0.61) | F10KLKB1 | |
| SCHEMBL2360325 | 0.83 | F10 (0.74) | F10KLKB1 | |
| SCHEMBL1064411 | 0.81 | HDAC1 (1.00) | HDAC3HDAC8HDAC1HDAC4HDAC7 | |
| SCHEMBL2325601 | 0.81 | HDAC1 (0.58) | F10HDAC3HDAC8HDAC1HDAC4 | |
| SCHEMBL4581337 | 0.81 | HDAC2 (0.74) | HDAC3HDAC8HDAC1HDAC2 | |
| SCHEMBL2828860 | 0.80 | HDAC1 (0.74) | HDAC3HDAC8HDAC1HDAC4HDAC7 | |
| SCHEMBL14155897 | 0.80 | HDAC3 (0.66) | F10HDAC3HDAC8HDAC1HDAC4 | |
| SCHEMBL7398572 | 0.79 | F10 (0.65) | F10KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | claimed |
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | claimed |
| EP-1495002-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | Astrazeneca AB (SE) | 2005-01-12 | — | — | EP | claimed |
| WO-2003087057-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | WO | claimed |
| EP-1495002-B1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-8247562-B2 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2012-08-21 | — | — | US | disclosed |
| EP-1949916-B1 | Chromatin remodeling agents for increasing expression of PDX-1 and promoting cell differentiation | LIFESCAN INC (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-1949916-A1 | Chromatin remodeling agents for increasing expression of PDX-1 and promoting cell differentiation | Lifescan, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080063628-A1 | METHODS TO PROMOTE CELL DIFFERENTIATION | LIFESCAN, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
| EP-1495002-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | Astrazeneca AB (SE) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087057-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | HDAC3, HDAC1, HDAC4 | F10 3874/4885HDAC3 1/4885HDAC8 8/4885 |
| US-20090029991-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | F10 3402/4885HDAC3 2/4885HDAC8 8/4885 |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC4 | F10 3678/4885HDAC3 1/4885HDAC8 8/4885 |
| US-20080063628-A1 | METHODS TO PROMOTE CELL DIFFERENTIATION | CTCF, CBX2, ZMYND8 | F10 3478/4885HDAC3 185/4885HDAC8 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.